The present invention relates to methods and pharmaceutical compositions for inhibiting influenza virus replication. More particularly, the present invention relates to a compound selected from the group consisting of Gemcitabine, Obatoclax Mesylate, Docetaxel, HA-14, Alsterpaullone, GSK3B inhibitor VIII, GSK3B inhibitor XV, Indirubin 3'- monoxime, L glutathione reduced, Fluocinolone acetonide, Tirofiban, Topotecan hydrochloride, Clofarabine, Vinblastine, Menadione Crystalline and derivatives or...

Disclosed are methods for reducing the risk of thrombocytopenia-associated mortality and morbidity, and for reducing the risk of becoming thrombocytopenic, in patients whose treatment requires inhibition of platelet aggregation. The methods involve administration of a pharmaceutically acceptable salt of tirofiban.

PURPOSE: A pharmaceutical composition containing an alkyl-substituted indene derivative containing novel pyridine, or pharmaceutically acceptable salts or isomers thereof is provided to prevent or treat PAR-1 related diseases, inflammation, or cancer. CONSTITUTION: An alkyl-substituted indene derivative containing pyridine is denoted by chemical formula 1. A pharmaceutical composition for preventing or treating PAR-1 activation-related diseases contains the indene derivative, salts, or isomers a...

Se describen métodos para reducir el riesgo de mortalidad y morbilidad asociadas a trombocitopenia y para reducir el riesgo de trombocitopenia en pacientes cuyo tratamiento requiere inhibición de la agregación plaquetaria. Los métodos involucran la administración de una sal farmacéuticamente aceptable de tirofiban la cual es el clorhidrato de tirofiban.